Search Results
Your search for Jo Cavallo matches 32 pages
Showing 1 - 32Olaparib/Temozolomide Shows Activity in Patients With Relapsed Small Cell Lung Cancer
Small cell lung cancer accounts for approximately 15% of all lung cancers and has high metastatic potential and poor clinical outcomes. While untreated small cell lung cancers are usually highly sensitive to cytotoxic chemotherapy—with response rates of between 50% and 70%—patients...
Survey Finds Rates of Physician-Patient Discussions About Lung Cancer Screening Are Declining
A study examining trends in patient-reported physician-patient discussions about lung cancer screening and the association of these discussions with smokers’ attempts to quit and intent to quit has found that discussions about screening have declined since 2012. Moreover, they were not...
Deep-Learning Model May Improve Predictions of Survival and Specific Outcomes in Lung Cancer
A study by Xu et al in Clinical Cancer Research evaluating deep-learning networks that analyze time-series computed tomography (CT) images of patients with locally advanced NSCLC has found these networks can integrate imaging scans at multiple time points to improve clinical outcome...
AACR 2019: Data Analysis Shows Activity of Pembrolizumab in Pretreated Patients With Advanced Small Cell Lung Cancer
The results of an analysis of pooled data from the phase Ib KEYNOTE-028 trial and the phase II KEYNOTE-158 study of the anti–programmed cell death protein 1 monoclonal antibody pembrolizumab in the treatment of advanced small cell lung cancer has found that the therapy provided antitumor...
AACR 2019: Liquid Biopsy–Based Test May Be Reliable in Identifying Treatment for Non–Small Cell Lung Cancer
The number of guideline-recommended biomarkers to be assessed in patients with newly diagnosed, metastatic non–small cell lung cancer (NSCLC) is increasing. These biomarkers include both predictive targets—including EGFR, ALK, ROS1, BRAF, RET, MET, and ERBB2—and prognostic...
Lung Cancer Mortality Among Women Projected to Increase by 43% Worldwide by 2030
According to a report by the International Agency for Research on Cancer, cancer is among the leading causes of morbidity and mortality worldwide, with an estimated incidence of 14 million new cases of the disease and 8.2 million cancer deaths in 2012. A study analyzing breast and female lung...
Large Disparities in Cancer Mortality Rates Found Among Different Racial/Ethnic Populations in New York State
According to the American Cancer Society, cancer is the leading cause of death for Hispanics and Asian/Pacific Islanders in the United States. However, their cancer burden is less than that of non-Hispanic whites and especially non-Hispanic blacks, who bear the most disproportionate share of the...
Risk-Prediction Tool Helps Tailor Lung Cancer Screening to Patient Preference and Clinical Benefit
A microsimulation model study found that the benefits of low-dose computed tomography (CT) screening for lung cancer varied substantially across the eligible population, with 3 factors being particularly influential: lung cancer risk, competing risks or life expectancy, and patient...
Researchers Identify Most Accurate Risk-Prediction Models for Lung Cancer Screening in Ever-Smokers
Recent lung cancer screening guidelines from the National Comprehensive Cancer Network(®) permit the use of risk models to refer ever-smokers for screening. However, different models select different screening populations and the performance of each model in selecting ever-smokers is...
By 2030, Prostate and Lung Cancers Are Expected to Be the Most Common Cancer Types Among HIV-Infected Adults
While effective antiretroviral therapy, which suppresses HIV replication and improves immune function, has resulted in increased longevity for people living with HIV and reduced the risk of certain cancers, including Kaposi sarcoma and non-Hodgkin lymphoma, other cancers are expected to become more ...
Study Cites Geographic Disparities in Lung Cancer Mortality Rates Among Women
According to the American Cancer Society, lung cancer is the leading cause of death among men and women, killing about 84,000 men and 71,000 women each year. Although lung cancer–related death rates in the United States have declined steadily since 1990 in men, they did not start to decline...
Study Suggests Racial Differences in Lung Tumor Biology
According to research by the American Cancer Society, lung cancer is the second most common cancer in men and women in the United States and is the leading cause of cancer-related death. In addition, among all populations, African Americans tend to have the highest lung cancer incidence and...
Potential Predictive Biomarker of Response to Crizotinib in Lung Cancer
Although the duration and magnitude of clinical response are unpredictable in patients with ALK-rearranged non–small cell lung cancer (NSCLC) treated with crizotinib (Xalkori), eventually all patients develop resistance to the drug. A study by Pailler et al evaluating whether circulating...
Combining AM0010 and Pembrolizumab Produced Antitumor Activity in Patients With Advanced Solid Tumors
A multibasket phase Ib study evaluating the clinical activity, tolerability, and antitumor activity of the cytokine-based immunotherapy AM0010 alone or in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda) has found that in monotherapy, objective responses to AM0010 were ...
Study Finds NSCLC to Be Genetically Different in Younger and Older Patients, Requiring Different Treatment Approaches
Unlike a number of other cancers in which young age at diagnosis is understood to represent distinct disease biology, the genomics and clinical characteristics of non–small cell lung cancer (NSCLC) in young patients are poorly understood. A study by Sacher et al investigating the relationship ...
KW-0761 May Reduce Immune System–Suppressing Treg Cells in Patients With Solid Tumors
A small phase Ia clinical trial investigating whether depleting immune cells called Tregs, which can inhibit anticancer immune responses, with KW-0761, a humanized anti-CCR4 monoclonal antibody, in patients with lung or esophageal cancer has found that the therapy dramatically reduced the number of ...
ECC 2015: Nivolumab Is More Effective Than Docetaxel in Extending Overall Survival in Advanced Nonsquamous NSCLC
A randomized phase III study by Borghaei et al evaluating the efficacy and safety of nivolumab (Opdivo) vs docetaxel in patients with advanced nonsquamous non–small cell lung cancer (NSCLC) after failure of platinum-based chemotherapy has found that nivolumab improved overall survival, 12.2...
Study Finds Annual Low-Dose CT Screening Effective in Identifying Precancerous Lung Nodules
A large international prospective study investigating the safety and effectiveness of using annual low-dose computed tomography (CT) as a screening tool to monitor nonsolid lung nodules has found that CT was accurate in identifying nodules that were likely to become cancerous. The study also found...
Long-Term Use of Statins May Reduce Risk of Lung Cancer Death
A large population-based British study of newly diagnosed patients with lung cancer has found that those who had prolonged use of statins, especially simvastatin, had a 19% reduction in lung cancer deaths. Among all patients, those who used statins in the year before their lung cancer diagnosis had ...
AZD9291 Shows Durable Responses in Patients With EGFR-Positive Lung Cancers
A clinical trial of the EGFR inhibitor AZD9291 in patients with advanced non–small cell lung cancer (NSCLC) who had disease progression after previous treatment with EGFR tyrosine kinase inhibitors has found that the drug was highly active—achieving a 95% disease control rate—in...
Study Finds Immunohistochemistry Is More Effective Than FISH in Detecting EML4-ALK Rearrangments in Lung Cancer
A retrospective study by Pekar-Zlotin et al investigating fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) for detecting EML4-ALK rearrangement in patients with lung cancer has found that FISH may miss a significant number of patients who tested positive with...
Study Finds Metformin May Reduce Lung Cancer Risk Among Diabetic Nonsmokers
A large retrospective cohort study of diabetic patients taking metformin, a first-line treatment for type II diabetes, has found that while metformin use was not associated with lower lung cancer risk overall, the risk was 43% lower among diabetic patients who had never smoked. In addition, the...
CDK7 Inhibitor Effective in Reducing Small Cell Lung Cancer in Preclinical Study
Although small cell lung cancer is an aggressive disease with a high mortality rate, in contrast to other lung carcinomas, there has not been significant progress in the development of therapies for the disease in more than 3 decades. Now, researchers using a high-throughput cellular screen of a...
Study Identifies Two Novel ALK Mutations Causing Lung Cancer Resistance to ALK Inhibitors
In a recent study investigating alectinib resistance in ALK-positive lung cancers, researchers identified two novel ALK mutations that are sensitive to ceritinib (Zykadia), a next-generation ALK tyrosine kinase inhibitor approved by the FDA earlier this year for advanced non–small cell lung...
National Lung Screening Trial Analysis Finds Low-Dose CT Screening Identifies More Lung Cancers in Older vs Younger Participants
Findings from the National Lung Screening Trial (NLST) showed that screening high-risk individuals (smoking history of ≥ 30 pack-years) aged 55 to 74 with low-dose computed tomography (CT) vs chest radiography reduced lung cancer mortality. Following the study results, the U.S. Preventive...
Combination Afatinib and Cetuximab Yields Benefit in Lung Cancer Patients Resistant to EGFR Inhibitors
A phase Ib study has found that a combination of the EGFR-targeted agents afatinib (Gilotrif) and cetuximab (Erbitux) yielded clinical responses in patients with EGFR-mutant lung cancer that had stopped responding to the EGFR inhibitors erlotinib (Tarceva) and gefitinib (Iressa). The combination...
Necitumumab Plus Chemotherapy Shows Overall Survival Benefit in Patients With Squamous NSCLC
In the large phase III SQUIRE trial of necitumumab (IMC-11F8) in combination with gemcitabine and cisplatin in the first-line treatment of advanced squamous non–small cell lung cancer (NSCLC), patients with stage IV metastatic disease showed a statistically significant improvement in overall...
Study Finds Possible New Gene Target for Lung Cancer
Researchers have identified a potential new gene mutation that may drive lung cancer development and growth. In a study in the Journal of Clinical Investigation by Imielinski et al, a patient with advanced lung cancer who was found to have the ARAF S214Csomatic gene mutation achieved nearly a...
Preclinical Study Suggests E-Cigarettes May Contribute to Lung Cancer in High-Risk Individuals
A study of human bronchial epithelial cells carrying mutations in the TP53 and KRAS genes has found that e-cigarette vapors enhanced the cells’ cancerous behaviors. The study suggests that e-cigarette exposure may contribute to lung cancer in individuals at high risk for the disease. The...
Imprime PGG Added to Chemoimmunotherapy Shows Improved Outcomes in Advanced Lung Cancer Patients
The addition of Imprime PGG, a type of immunotherapy, to chemoimmunotherapy with carboplatin, paclitaxel, and cetuximab (Erbitux) resulted in improved response rates and overall survival rates in patients with late-stage, non–small cell lung cancer (NSCLC), according to the results of a phase ...
New Plasma Biomarker Identified for the Diagnosis of Lung Cancer
A new plasma biomarker, isocitrate dehydrogenase 1 (IDH1), has been shown to be more sensitive in detecting non–small cell lung cancer (NSCLC) than currently used biomarkers, including CEA, Cyfra21-1, and CA125, according to a study published in Clinical Cancer Research. The study by Jie He,...
Survival Advantage Seen in Foreign-Born Hispanics With NSCLC
Foreign-born Hispanics with non–small cell lung cancer (NSCLC) have a decreased risk of disease-specific mortality compared with non-Hispanic whites and United States-born Hispanics with NSCLC, according to a study published in the Journal of Clinical Oncology. Manali I. Patel, MD, and...
